Merrimack To Present At Multiple Investor Conferences This Spring

CAMBRIDGE, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that their management team is scheduled to present at multiple investor conferences this spring.

Bank of America Merrill Lynch Healthcare Conference
  • Date: Tuesday, May 14, 2:20 p.m. PT
  • Venue: Encore at the Wynn, Las Vegas, Nevada
  • Speaker: Robert Mulroy, President & Chief Executive Officer

UBS Global Healthcare Conference
  • Date: Monday, May 20, 10:30 a.m. ET
  • Venue: Sheraton New York Hotel, New York, New York
  • Speaker: William Sullivan, Chief Financial Officer

Jefferies 2013 Global Healthcare Conference
  • Date: Tuesday, June 4, 9:30 a.m. ET
  • Venue: Grand Hyatt, New York, New York
  • Speaker: Robert Mulroy, President & Chief Executive Officer

For up-to-date information on presentation dates and times, please visit the events page in the Investors section of Merrimack's website at http://investors.merrimackpharma.com . Live webcasts of these conference presentations also can be accessed by visiting the Investors section of the company's website. Replays of the webcasts will be archived on Merrimack's website for two weeks following the presentations.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development.

Forward-looking statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
CONTACT: Media Contacts:         Kathleen Petrozzelli Gallagher, Merrimack         617-441-1043         kgallagher@merrimackpharma.com                  Liz Bryan, Spectrum         202-955-6222         lbryan@spectrumscience.com

If you liked this article you might like

Verastem Shares Are Exploding 50% -- Here's Why

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Trevena, Synergy Lead Biotech Movers

These 5 Stocks Under $10 Could Explode Up Soon